Grace Therapeutics (GRCE) Accounts Payables (2017 - 2026)
Grace Therapeutics (GRCE) posted Accounts Payables of $702000.0 for Q1 2026, up 515.79% sequentially from $114000.0 in Q4 2025, and down 63.63% YoY from $1.9 million in Q1 2025.
Grace Therapeutics (GRCE) Accounts Payables (2017 - 2026) Analysis & Trends
Grace Therapeutics has reported Accounts Payables for 10 years, with the latest figure at $702000.0 in Q1 2026.
- Quarterly Accounts Payables fell 63.63% year-over-year to $702000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $702000.0 (down 63.63% YoY) and the FY2026 annual result came in at $702000.0, down 63.63% from the prior year.
- Accounts Payables grew to $702000.0 in Q1 2026 per GRCE's latest filing, from $114000.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $3.7 million in Q3 2022 and troughed at $114000.0 in Q4 2025.
- A 5-year average of $2.0 million and a median of $1.9 million in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2023 and 2025: Accounts Payables surged 98.81% in 2023, then tumbled 94.22% in 2025.
- Over 5 years, Accounts Payables stood at $3.4 million in 2022, then sank by 48.04% to $1.7 million in 2023, then rose by 12.89% to $2.0 million in 2024, then sank by 94.22% to $114000.0 in 2025, then soared by 515.79% to $702000.0 in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $702000.0, $114000.0, and $459000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 35.57 Mn |
| 10 | Grace Therapeutics | 37.72 Mn | 37.72 Mn | - | 1.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.25 Mn |
| Mar 31, 2026 | 702,000.00 |
| Dec 31, 2025 | 114,000.00 |
| Sep 30, 2025 | 459,000.00 |
| Jun 30, 2025 | 2.32 Mn |
| Mar 31, 2025 | 1.93 Mn |
| Dec 31, 2024 | 1.97 Mn |
| Sep 30, 2024 | 1.68 Mn |
| Jun 30, 2024 | 2.60 Mn |
| Mar 31, 2024 | 1.68 Mn |
| Dec 31, 2023 | 1.75 Mn |
| Sep 30, 2023 | 1.35 Mn |
| Jun 30, 2023 | 1.89 Mn |
| Mar 31, 2023 | 3.34 Mn |
| Dec 31, 2022 | 3.36 Mn |
| Sep 30, 2022 | 3.74 Mn |
| Jun 30, 2022 | 3.06 Mn |
| Mar 31, 2022 | 1.68 Mn |
| Dec 31, 2021 | 2.84 Mn |
| Sep 30, 2021 | 4.43 Mn |